RYM · NZX
Ryman Healthcare is an NZX-listed retirement living company covered by Annolyse across HY26. This page brings together the latest briefing, the current metrics snapshot, and the published history to date in one place.
Snapshot
HY26, released 27 November 2025
| Metric | Value |
|---|---|
| Revenue | $413.8m |
| EBITDAF | $40.1m |
| NPAT | -$45.2m |
| Operating cash flow | $172.9m |
| OCF / EBITDAF % | 430.9% |
| Net debt | $1653.7m |
| Net debt / EBITDAF | 41.20x |
| ROE % | -1.1% |
| PBT | -$40.2m |
| FCF pre-lease | $59.5m |
Longitudinal view
Current-period values from each published briefing, with the most recent reporting period shown first.
| Metric | HY266 MONTHS27 November 2025 |
|---|---|
| Revenue | $413.8m |
| Revenue growth % | 13.0% |
| EBITDAF | $40.1m |
| EBITDAF margin % | 9.7% |
| PBT | -$40.2m |
| NPAT | -$45.2m |
| Operating cash flow | $172.9m |
| OCF / EBITDAF % | 430.9% |
| FCF pre-lease | $59.5m |
| FCF post-lease | $56.2m |
| ROE % | -1.1% |
| Net debt | $1653.7m |
| Net debt / EBITDAF | 41.20x |
| Debtor days | 10 |
| Inventory days | 0 |
| Total assets | $12149.6m |
Source: annolyse.ai/companies/rym
Accountability
Read the prior briefing's expectations and unresolved questions alongside the subsequent result, without forcing long-form editorial text into narrow cards.
Once a second briefing exists for this company, this section will compare the previous briefing's expectations and unresolved issues with what actually happened in the next result.
Archive
Every published Annolyse briefing for this company appears here in reverse chronological order.
Subscribe
Subscribe to get future Annolyse briefings as soon as they are published.